HIV Drug-resistant Strains as Epidemiologic Sentinels
María S. Sánchez* , Robert M. Grant†, Travis C. Porco‡, and Wayne M. Getz*
Author affiliations: *University of California, Berkeley, California, USA; †Gladstone Institute of Virology and Immunology, San Francisco, California, USA; ‡California Department of Health Services, Berkeley, California, USA
Figure 1. Flow chart of the different categories and flows considered in our model system. For simplicity, we considered 1 type of treatment when analyzing the effects of an increase in high-risk behavior and treatment delay. When considering the effects of overall change in treatment strategy, all categories and flows were included in the analysis. Abbreviations: m, mortality (composed of background deaths for all categories, and for persons in the chronic phase of infection, HIV-related deaths are included); Rx, treatment; R, resistance; M, monotherapy; H, highly active antiretroviral therapy (HAART). Color code for the categories' encircling ovals: black (uninfected); purple (wild type); blue (monotherapy resistant strain); green (HAART-resistant strain). Background code of oval categories: no fill (untreated); tan (monotherapy); gray (HAART). Code for the categories' encircling ovals: single, no staging (uninfected and acutely infected); double, staged categories (persons in the chronic phase).
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.